Sentence examples for reduction of flares from inspiring English sources

39 Improvement in AE was measured by three basic methods, Eczema Area Severity Index (EASI), Investigators' Global Assessment IGAandand reduction of flares needing topical corticosteroids.

Treating to target sUA comprises the concept that ULT should reach and maintain steady subsaturating sUA levels in plasma in the long term [ 2, 3], that is sUA at least lower than 6 mg/dl (360 µmol/L) in all patients with gout, as there is compelling evidence that getting to this minimum target is associated with reduction of flares and tissue deposits [ 48].

Retrospective analysis of the use of adalimumab, etanercept and infliximab in the treatment of spondyloarthritides indicated that etanercept treatment led to a smaller reduction of uveitis flares than the other two agents studied and, in addition, flares of uveitis have been reported in patients starting etanercept therapy.

Also, in patients with a history of chronic uveitis, a reduction of AU flares during the study was observed.

Long-term safety and efficacy data on tophus diminishment and reduction of gout flares have recently become available.

This might be one of the reasons that no differences in reduction of gout flares were seen.

Long-term safety data and efficacy data on tophus diminishment and reduction of gout flares have recently become available.

In two large, phase III trials of belimumab combined with standard therapy, treated patients had a better outcome at 1 year than patients treated with standard therapy alone, including a difference in the number of patients achieving the SRI, a reduction in the risk of flares and severe flares, and an overall reduction in prednisone use.

We herein report that a single dose of canakinumab, 50 300 mg, or 4-weekly doses given over 4 months (two doses of 50 mg and two of 25 mg) produced a 62% to 72% reduction in the mean number of flares per patient and a 64%to72%2% reduction in the risk of experiencing ≥1 flare at 16 weeks compared with colchicine.

Determining the duration of the therapeutic effect is critical, because the observed reduction in number and severity of flares and a decreased overall steroid dose even at 76 weeks could all contribute to significant long-term benefits.

According to this analysis, there was a 62% to 72% reduction in the mean number of flares per patient for canakinumab doses ≥50 mg versus colchicine (rate ratio: 0.28 0.38, p≤0.0083) (table 2).